A new reverse-phase high performance liquid chromatographic method for determination of flutamide in liposomes, rat blood plasma and tablet dosage forms;Un nuevo método de cromatografía de líquidos de alto rendimiento y de fase inversa para la determinación de flutamida en liposomas, plasma de sangre de rata y formas de dosificación en comprimidos

Ars Pharmaceutica

Volumn 46, Issue 2, 2005, Pages 109-124

  Umrethia, M L ^a   Ghosh, P K ^a   Majithiya, R J ^a   Murthy, R S R ^a,b  

^a M S UNIVERSITY OF BARODA   (India)

^b GH Patel Pharmacy Building   (India)

Author keywords

Flutamide; Reverse Phase High Performance Liquid Chromatography

Indexed keywords

FLUTAMIDE; LIPOSOME; MERCAPTOPURINE; METHANOL; WATER;

ACCURACY; ARTICLE; COLUMN CHROMATOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG MONITORING; FLOW RATE; NONHUMAN; RAT; REPRODUCIBILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SAMPLING; STANDARD; TABLET FORMULATION; TECHNIQUE; VALIDATION PROCESS;

EID: 24644459343     PISSN: 00042927     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Goldspiel BR, Kholer DR, Flutamide: an antiandrogen for advanced prostate cancer. Drug Intelligence and Clinical Pharmacy 1990; 24: 611-623.
2. Berson A., Wolf C., Chachaty C., Metabolic activation of the nitro aromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies J.Pharmacol.Exp.Ther. 1993; 265: 366-372.
3. Schulz M., Schmoldt A., Donn F., Becker H., The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur.J.Clinical. Pharmacol. 1988; 34: 633-636.
4. Brogden R., Clissold S., Flutamide: A preliminary review of its pharmacodynamic and pharmacokinetics properties, and its therapeutic efficacy in advanced prostate cancer. Drugs 1989; 38:185-203.
5. Aso Y., Akaza H., Koiso K., Kumamoto Y., Hawai T., Origasa S., Hinyokika Kiyo 1993; 39: 381-389.
6. Chabner BA, Allegra CJ, Curt CA, Calabresi P., in: A. Goodman, J.G. Hardman, L.E. Limbird, P.B. Milinoff, R.W. Ruddan (Eds.), The Pharmacological Basis of Therapeutics, 9th ed., Mc-Graw Hill, Mexico, 1996, pp. 1309-1367.
7. Squella JA, Pena C., Alvarez-Lueje A., Electrochemical Study of Flutamide, an Anticancer Drug, and Its Polarographic, UV Spectrophotometric and HPLC Determination in Tablets. Electroanalysis 1998;10(15): 1043-51.
8. Miranda A, Caraballo I, Millan M., Stability study of flutamide in solid state and in aqueous solution. Drug Dev. Ind. Pharm. 2002; 28(4): 413 - 422.
9. Campanero MA, Sacaba B, Garcia-Quelglas E, Development of a sensitive method for the determination of ganciclovir by reversed-phase high-performance liquid chromatography J.Chromatogr.B 1998; 706: 311-317.
10. Zhong Z, Yum KT, Diakur J, Hydroxypropyl-β-cyclodextrin flutamide inclusion complex II: Oral and intravenous pharmacokinetics in rats. J.Pharm.Pharmaceut.Sci, 2002; 5(3): 292-298.
11. Bangham AD, Standish MM, Watkins JC, Preparation of multilamellar vesicles of defined size-distribution by solventspherule evaporation. J. Mol. Biol. 1965; 13: 238-252.
12. Betagiri GV, Jenkins SA, Parsons DL, Liposomal Drug Delivery Systems, tenth ed., Technomic Publications, Lancaster, 1993.
13. Merodia M, Mirshahi T, Mirshahi M, Development of a sensitive method for the determination of ganciclovir by reversedphase high-performance liquid chromatography J.Chromatogr. 2000; 870: 159-167.
14. Bhalerao SS, Harshal AR, Preparation, optimization, characterization, and stability studies of salicylic acid. Drug Dev. Ind. Pharm. 2003; 29(4): 451-467.
15. Winefordner JD, Long GL, Limit of detection. A closer look at the IUPAC definition. Anal. Chem. 1983; 55: 712A-724A.
16. ICH Topic Q2B, Pharmaeuropa, 8. 1996; 108-111.